About Pain
Pain is defined as a complex medical problem that can have profound effects not only on one's physical but also mental well-being. Pain management is a branch of medicine, which employs approach for easing the suffering and improving the quality of life of individuals suffering from pain. It can be simple or complex type, depending on the cause of pain. Pain management comprises of a variety of skills and techniques used for the treatment of pain.
Technavio’s analysts forecast the global pain management drugs market to grow at a CAGR of 4.97% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global pain management drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs that are used for the management of pain.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Pain Management Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Endo International
• Johnson & Johnson
• Pfizer
• Purdue Pharma
Other prominent vendors
• Allergan
• AstraZeneca
• Baxter
• Bayer
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Durect
• GlaxoSmithKline
• Hospira
• Merck
• Novartis
• Pain Therapeutics
• F. Hoffmann-La Roche
• Sanofi
• UCB
• Valeant
• Taro Pharmaceuticals
• Achelios Therapeutics
• Alder Biopharmace-uticals
• Amgen
• CoLucid
• Daiichi Sankyo
• Dr. Reddy's Laboratories
• Eli Lilly
• GW Pharmaceuticals
• Immune Pharmaceuticals
• Innovative Med Concepts
• NeurAxon
• OptiNose
• RedHill
• Sorrento Therapeutics
• SUDA
• Teva
• Tonix
• Trigemina
• WEX Pharmaceuticals
• Zynerba Pharmaceuticals
Market driver
• Increase in awareness of pain management drugs
• For a full, detailed list, view our report
Market challenge
• Preference for alternative therapies
• For a full, detailed list, view our report
Market trend
• Off-label drug usage
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Assessment of pain
• Treatment
PART 05: Pipeline portfolio
• Information on pipeline candidates
PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: Market segmentation by drug class
• Opioids
• NSAIDs
• Other
• Global opioids market
• Global NSAIDs market
PART 08: Market segmentation by type
• Musculoskeletal pain
• Surgical and trauma pain
• Cancer pain
• Neuropathic pain
• Migraine pain
• Obstetrical pain
• Fibromyalgia pain
• Burn pain
• Dental/facial pain
• Pediatric pain
• Global musculoskeletal pain drugs market
• Global surgical and trauma pain drugs market
• Global cancer pain drugs market
• Global neuropathic pain drugs market
• Global migraine pain drugs market
• Global obstetrical pain drugs market
• Global fibromyalgia pain drugs market
• Global burn pain drugs market
• Global dental/facial pain drugs market
• Global pediatric pain drugs market
PART 09: Geographical segmentation
• Pain management drugs market in Americas
• Pain management drugs market in EMEA
• Pain management drugs market in APAC
PART 10: Market drivers
• Rise in older population
• Promising pipeline
• Increase in awareness of pain management drugs
• Favorable regulatory scenario
PART 11: Impact of drivers
PART 12: Market challenges
• Generic competition
• Adverse effects
• Preference for alternative therapies
• Short-term relief
• Threat of counterfeit products
PART 13: Impact of drivers and challenges
PART 14: Market trends
• Increase in R&D activities
• Off-label drug usage
• Strategic alliances
PART 15: Vendor landscape
• Competitive scenario
• AstraZeneca
• Endo International
• Johnson & Johnson
• Pfizer
• Purdue Pharma
• Other prominent vendors
• List of abbreviations
PART 16: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Pain assessment
Exhibit 03: Types of pain scales
Exhibit 04: Treatment options for pain
Exhibit 05: Commonly used non-opioids for pain management
Exhibit 06: Commonly used adjuvant medicines for pain
Exhibit 07: Pain management
Exhibit 08: Pipeline portfolio: Major drug candidates under development for pain management
Exhibit 09: Global pain management drugs market 2015-2020 ($ billions)
Exhibit 10: Five forces analysis
Exhibit 11: Global pain management drugs market by drug class
Exhibit 12: Segmentation of global pain management drugs market by drug class, 2015
Exhibit 13: Global opioids market 2015-2020 ($ billions)
Exhibit 14: Key drivers and challenges of global opioids market
Exhibit 15: Global NSAIDs market 2015-2020 ($ billions)
Exhibit 16: Key drivers and challenges of global NSAIDs market
Exhibit 17: Global pain management drugs market segmentation by type
Exhibit 18: Global pain management drugs market segmentation 2015
Exhibit 19: Global musculoskeletal pain drugs market 2015-2020 ($ billions)
Exhibit 20: Global surgical and trauma drugs market 2015-2020 ($ billions)
Exhibit 21: Global cancer pain drugs market 2015-2020 ($ billions)
Exhibit 22: Global neuropathic pain drugs market 2015-2020 ($ billions)
Exhibit 23: Global migraine pain drugs market 2015-2020 ($ billions)
Exhibit 24: Global obstetrical pain drugs market 2015-2020 ($ billions)
Exhibit 25: Global fibromyalgia pain drugs market 2015-2020 ($ billions)
Exhibit 26: Global burn pain drugs market 2015-2020 ($ billions)
Exhibit 27: Global dental/facial pain drugs market 2015-2020 ($ billions)
Exhibit 28: Global pediatric pain drugs market 2015-2020 ($ billions)
Exhibit 29: Global pain management drugs market by type: YoY revenue and growth 2015-2020
Exhibit 30: Global pain management drugs market by geographical segmentation 2015
Exhibit 31: Global pain management drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 32: Pain management drugs market in Americas 2015-2020 ($ billions)
Exhibit 33: Pain management drugs market in EMEA 2015-2020 ($ billions)
Exhibit 34: Pain management drugs market in APAC 2015-2020 ($ billions)
Exhibit 35: Global pain management drugs market: YoY revenue and growth based on geography 2015-2020
Exhibit 36: Impact of drivers
Exhibit 37: Challenges in global pain management drugs market
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Trends in global pain management drugs market
Exhibit 40: AstraZeneca: Key pain products segmentation by revenue 2014
Exhibit 41: AstraZeneca: YoY growth rate and revenue of Vimovo 2012-2014 ($ millions)
Exhibit 42: AstraZeneca: Key takeaways
Exhibit 43: Endo International: YoY growth rate and revenue of Opana ER 2012-2014 ($ millions)
Exhibit 44: Endo International: YoY growth rate and revenue of Voltaren 2012-2014 ($ millions)
Exhibit 45: Endo International: YoY growth rate and revenue of Lidoderm 2012-2014 ($ millions)
Exhibit 46: Endo International: YoY growth rate and revenue of Percocet 2012-2014 ($ millions)
Exhibit 47: Endo International: Key takeaways
Exhibit 48: Johnson & Johnson: Key takeaways
Exhibit 49: Pfizer: YoY growth rate and revenue of Lyrica 2012-2014 ($ billions)
Exhibit 50: Pfizer: YoY growth rate and revenue of Celebrex 2012-2014 ($ billions)
Exhibit 51: YoY growth rate and revenue of Relpax 2012-2014 ($ millions)
Exhibit 52: Pfizer: Key takeaways
Exhibit 53: Purdue Pharma: Key takeaways
